Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, is
investigating Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) ("Aegerion")
for securities fraud following the news that the company illegally
engaged in off-label marketing schemes and advises investors of the
class-action lead plaintiff deadline on March 17, 2014. Persons with
information or who have suffered financial losses can contact a Hagens
Berman attorney by emailing Aegerion@hbsslaw.com.
The securities fraud class-action lawsuit, filed on Jan. 15, 2014, on
behalf of investors who purchased stock between March 15, 2012 and Jan.
9, 2014 (the "Class Period"), alleges that Aegerion jeopardized the
investments of its shareholders by violating FDA and FDCA regulations
regarding the marketing of prescription drugs. For more
information about the suit, please contact Hagens Berman Partner Reed
Kathrein, who is leading the firm's investigation, by calling
510-725-3000. Additional information is available at http://hb-securities.com/investigations/Aegerion.
The complaint alleges that Aegerion, a biopharmaceutical company,
violated FDA regulations by directly marketing a drug for a use other
than for the FDA approved indication while intentionally withholding
this information from investors. The company is engaged in development
and commercialization of therapeutics to treat debilitating and fatal
rare diseases, according to the complaint. Violating the FDA's
regulations regarding this kind of off-label marketing can greatly
jeopardize the financial stability of a company, potentially resulting
in fines and other penalties, the complaint states.
News reports on Nov. 8, 2013, revealed Aegerion CEO, Marc D. Beer, had
received warning letters from the FDA about these violations, according
to the filing. Following these reports, the U.S. Department of Justice
subpoenaed the company for documents regarding its marketing and sale of
its drug, JUXTAPID. At the time this news became public, Aegerion shares
declined $7.98 per share, or nearly 11 percent, to close at $65.77 per
share on Jan. 10, 2014.
Additionally, the complaint states that company insiders sold almost one
million shares of Aegerion stock, yet did not purchase any Aegerion
shares. One month prior to receiving the FDA's warning letter, Beer sold
40,000 Aegerion shares and more than 700,000 options, according to the
suit filed. Other company insiders behaved similarly.
"Tactics like the ones put in place by Aegerion appear to be blatant
violations of federal regulations and set the company up to be penalized
heavily by government agencies," said Mr. Kathrein. "They made a choice
to withhold these risky and potentially illegal behaviors from investors
and engage in insider trading. Moves like these clearly put shareholders
in jeopardy for the sake of those running the company."
The deadline to file for lead plaintiff in a recently filed securities
fraud class action is March 17, 2014.
Persons with non-public information should consider their options to
help in the investigation or take advantage of the SEC Whistleblower
program. Under the new SEC Whistleblower program, whistleblowers who
provide original information may receive rewards totaling up to 30
percent of any successful recovery made by the SEC.
Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law
firm with offices in nine cities. The Firm represents investors,
whistleblowers, workers and consumers in complex litigation. More about
the law firm and its successes can be found at www.hb-securities.com.
Read the Firm's Securities Newsletter at http://www.hb-securities.com/newsletter.
The firm's blog is located at www.meaningfuldisclosure.com.
[ Back To NFVZone's Homepage ]